Skip to main content
SpringerLink
Log in

Farmaci anti tiroidei in gravidanza: controversie sul rischio di malformazioni congenite

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

Negli ultimi cinque anni sono stati pubblicati sei studi internazionali, finalizzati a rivelare malformazioni congenite (birth defects) associate al trattamento con ATD (MMI e PTU) in gravidanza, giunti a conclusioni differenti. In due studi è stato rilevato un significativo maggiore rischio di “difetti di nascita” in nati da madri esposte agli ATD (in particolare MMI) nel corso del primo trimestre di gestazione. Gli altri quattro studi giungono a conclusioni sostanzialmente negative. Questa rassegna esamina criticamente i risultati di tali studi e raccomanda di considerare il problema con attenzione e con prudenza in attesa di futuri studi focalizzati sulla sicurezza per la madre e il bambino.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Kriplani A, Buckshee K, Bhargava VL et al. (1994) Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol 54(3):159–163

    Article  CAS  PubMed  Google Scholar 

  2. Marino M, Latrofa F, Menconi F et al. (2014) An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Invest 37:1041–1048

    Article  CAS  PubMed  Google Scholar 

  3. Milham SJ, Elledge W (1972) Maternal methimazole and congenital defects in children. Teratology 5:125–126

    Article  Google Scholar 

  4. FDA Drug Safety Communication (2010) New boxed warning on severe liver injury with propylthiouracil. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023.htm (accesso effettuato il 16/03/2016)

  5. Laurberg P, Andersen SL (2015) Antithyroid drug use in pregnancy and birth defects: why some studies find clear associations, and some studies report none. Thyroid 25:185–190

    Article  Google Scholar 

  6. Yoshihara A, Noh J, Yamaguchi T et al. (2012) Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97:2396–2403

    Article  CAS  PubMed  Google Scholar 

  7. Andersen SL, Olsen J, Wu CS, Laurberg P (2013) Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 98:4373–4381

    Article  CAS  PubMed  Google Scholar 

  8. Chen CH, Xirasagar S, Lin CC et al. (2011) Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. BJOG 118:1365–1373

    Article  CAS  PubMed  Google Scholar 

  9. Korelitz JJ, McNally DL, Masters MN et al. (2013) Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid 23:758–765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lo JC, Rivkees S, Chandra M et al. (2015) Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid 25:698–705

    Article  CAS  PubMed  Google Scholar 

  11. Gianetti E, Russo L, Orlandi F et al. (2015) Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest 38:977–985

    Article  CAS  PubMed  Google Scholar 

  12. http://www.farmaciegravidanza.gov.it/content/metimazolo-carbimazolo (accesso effettuato il 16/03/2016)

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Aalborg University Hospital, Aalborg, Danimarka

    Peter Laurberg & Stine Linding Andersen

  2. Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Danimarka

    Peter Laurberg

  3. Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Danimarka

    Stine Linding Andersen

  4. Accademia Peloritana dei Pericolanti, Università di Messina, Messina, Italia

    Francesco Trimarchi

Authors
  1. Peter Laurberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stine Linding Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Trimarchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Trimarchi.

Ethics declarations

Conflitto di interesse

Gli autori Peter Laurberg, Stine Linding Andersen e Francesco Trimarchi dichiarano assenza di conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi su animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposta da Francesco Trimarchi.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 26 kB)

(DOC 25 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laurberg, P., Linding Andersen, S. & Trimarchi, F. Farmaci anti tiroidei in gravidanza: controversie sul rischio di malformazioni congenite. L'Endocrinologo 17, 78–81 (2016). https://doi.org/10.1007/s40619-016-0181-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-016-0181-2

Parole chiave

Search

Navigation